burger

A pharmaceutical company
specialising in biological
medicinal products

15 medicines

prescribed to

hospital

3 fields of therapy
  • Immunology
  • Haemostasis
  • Intensive Care
4

BIOPRODUCTION SITES in the world

2/3

of LFB’s biomedicinal products are intended for the treatment of patients with rare diseases

Group executive committee

Committee’s composition
€362M in turnover

in 2020

1 of the leaders in France

IN THE FIELD OF PLASMA-DERIVED MEDICINAL PRODUCTS

All news

3:00

LFB alongside the ADAAT association

3:32

Part 1: three years of LFB transformation

2:38

Part 2 : the new Momentum

3:13

Part 3 : LFB's values

All videos

Interview with Denis Delval

Bruno de Miribel joins LFB

LFB alongside the ADAAT association

Three years of LFB transformation - Part 2 The New Momentum

Three years of LFB transformation - Part 3 The LFB's values

LFB works for « the France of tomorrow » and unveils a new industrial project in Alès

EMA acceptance for filing of the MARKETING AUTHORISATION application FOR EPTACOG BETA, THE LFB RECOMBINANT FACTOR VIIA , AND PUBLICATION OF THE EXPLORATORY IN VITRO STUDY RESULTS on eptacog beta in combination with emicizumab

LFB 2021 corporate Brochure

3:00

LFB alongside the ADAAT association

there is 5 months

3:13

Part 3 : LFB's values

there is 8 months

2:38

Part 2 : the new Momentum

there is 8 months

3:32

Part 1: three years of LFB transformation

there is 9 months